Radiology deal flow is splitting in two: $8B radiopharma and 14-state mobile imaging rollups

Curium’s agreement to buy Lantheus for up to $8 billion is the kind of number that grabs attention. But for hospital imaging leaders, the more consequential shift in 2026 radiology M&A may be quieter: consolidation is branching into two separate operating models, and each one changes a different set of contracts, workflows, and vendor dependencies.

One track is upstream scale, radiopharmaceuticals, imaging components, and teleradiology networks stitching together global coverage. The other is capacity delivery, mobile scanners, leased equipment, and outsourced service lines that let small and rural facilities buy throughput without building a full department. Both are visible across recent deal reporting collected by Radiology Business, and both land directly on procurement and operations, even when the press release language stays high-level.

Upstream deals are getting bigger, and closer to the supply chain

Radiology Business reported Aug. 3 that Curium signed a definitive deal to acquire Lantheus for up to $8B, after Bloomberg had earlier reported on July 27 that Curium was closing in on a transaction valued around $7B. The move matters operationally because radiopharma is not a “background” input for PET and nuclear medicine programs. It is a time-sensitive, logistics-heavy supply chain that touches scheduling windows, dose availability, and service continuity.

Radiology Business also reported Teledyne’s plan to acquire Varex Imaging in a $1.1B deal, with a stated integration intent: folding Varex X-ray tubes, digital detectors, and related technologies into Teledyne’s medical imaging portfolio. For hospital operators, component consolidation can show up as product roadmap consolidation, longer refresh-cycle commitments, or changes in service parts availability, all of which end up in capital planning and service contract negotiations.

On the reading side, Radiology Business reported that Radiology Partners reached a definitive deal to buy London-based Everlight Radiology for a reported $715M. Everlight employs about 800 physicians providing reads across multiple countries, according to Radiology Business. For CIOs and imaging informatics teams, the operational question is less “who owns whom” and more whether cross-border teleradiology scale brings standard interfaces, credentialing automation, and measurable coverage resilience, or just a larger set of integrations to keep running.

Platform rollups are moving the scanner to the patient

The second track is not centered on upstream technology portfolios. Instead, it focuses on how imaging capacity is bundled and provided to facilities that lack the volume, staffing, or capital to operate every modality in-house.

Radiology Business reported June 4 that Align Capital Partners agreed to acquire Heritage Imaging for an undisclosed sum. Heritage, founded in 1989 and based in Boise, provides diagnostic imaging to underserved and rural markets across the Midwest and Pacific Northwest, according to Radiology Business. The company serves facilities in 14 states and delivers scans via fully staffed mobile solutions and leased equipment offerings, spanning PET-CT, MRI, nuclear medicine, ultrasound, and echocardiography, among other modalities.

Those details are the operational core. A mobile-and-leasing model changes how a critical access hospital thinks about coverage, uptime, and staffing. Instead of funding a permanent suite and recruiting scarce technologists, the facility can contract for a schedule and a service level. The trade is governance. Credentialing, protocol standardization, contrast and radiopharma coordination, and image routing into PACS and downstream reporting all have to be tight, or the “capacity” arrives but the throughput does not.

Radiology Business noted Heritage has completed three add-on acquisitions since 2024 and plans further M&A with Align. That implies the model is being scaled geographically, and that matters for health systems with dispersed footprints where one enterprise imaging strategy now has to accommodate rotating assets, traveling staff, and multiple local clinical stakeholders.

Integration is where the savings, and the delays, are created

Radiology Today’s Michael Mahoney, writing in “Managing to Succeed: Radiology Mergers,” frames consolidation as a management exercise that succeeds or fails on execution, aligning people, process, and governance after the transaction closes. That maps cleanly to what imaging operators experience: the systems that determine patient access are scheduling templates, protocol libraries, staffing coverage, and IT interoperability, not the deal headline.

Older guidance in the radiology literature makes the same point in a more basic way. A review article indexed on PubMed (“Mergers and acquisitions for the radiologist”) describes M&A success as driven by the approach and process, and it flags that radiology has relatively little published operational guidance on the logistics and pitfalls. For health systems, that lack of standard playbooks is a signal: integration work tends to be bespoke, so it needs explicit resourcing and timeline discipline, especially when modalities and sites are being added through serial acquisitions.

Where this lands in contracts being written now

Consolidation is often sold as “scale,” but operationally it shows up as different levers depending on which track a deal sits in. Upstream combinations, like Curium and Lantheus or Teledyne and Varex, can change the vendor map behind nuclear medicine and imaging equipment, which then changes service terms, parts logistics, and upgrade options. Capacity-platform deals, like Align’s acquisition of Heritage, change how facilities buy access to PET-CT and MRI in the first place, shifting spend from capital and recruitment into multi-year service commitments.

That split is useful for operators because it clarifies what to evaluate. A radiopharma or component deal should trigger roadmap diligence and supply continuity questions. A mobile imaging platform deal should trigger interface diligence, clinical governance checks, and explicit service-level definitions for when the unit is late, down, or staffed short.

Questions for imaging ops and procurement teams after the Heritage and Curium headlines

• For mobile imaging contracts: what is the guaranteed operating schedule by modality, and what is the make-up policy when the mobile unit is down or delayed? Tie it to measurable reschedule time, not “best efforts.”
• For PACS/RIS integration: who owns interface monitoring and after-hours support when studies are produced offsite or by rotating teams? Require named escalation paths and response-time targets.
• For radiopharma and nuclear medicine growth plans: after Curium’s definitive agreement for Lantheus (reported by Radiology Business), when do product, distribution, or contracting changes take effect, and what is the process for notifying sites so scheduling templates and ordering can be updated in time.